Teleflex presents clinical data on UroLift and Barrigel products By Investing.com
Teleflex Incorporated announced new clinical data for its UroLift System and Barrigel rectal spacer at recent medical conferences. The UroLift study showed a significantly lower rate of catheterization compared to a competitor, while the Barrigel study indicated zero percent Grade 2+ toxicity at three years. Despite a planned divestiture of its Interventional Urology unit, Teleflex is expected to maintain profitability and stock value.
Diamond Hill Capital Management Inc. Boosts Position in Teleflex Incorporated $TFX
Diamond Hill Capital Management Inc. increased its stake in Teleflex Incorporated (NYSE:TFX) by 6.3% in the fourth quarter, now owning 349,809 shares valued at $42.7 million. This comes as Teleflex reported strong quarterly results, exceeding analyst expectations for EPS and revenue, and announced a quarterly dividend of $0.34 per share. Despite mixed analyst sentiment with a "Hold" consensus, institutional investors hold a significant 95.62% of the company's shares.
Teleflex Shareholders Endorse Directors, Pay and Auditor
Teleflex shareholders have approved all seven director nominees, executive compensation, and the reappointment of PricewaterhouseCoopers LLP as the independent auditor at their 2026 annual meeting. These decisions indicate strong investor confidence in the company's leadership and corporate governance. Despite some profitability concerns, Teleflex's positive cash flow, reaffirmed guidance, and strategic financial actions are noted by analysts.
Teleflex Inc. stock underperforms Thursday when compared to competitors
Teleflex Inc. (TFX) shares dropped 2.43% on Thursday, closing at $131.90, despite an overall positive trading session for the broader stock market. The S&P 500 Index and Dow Jones Industrial Average both saw gains, while Teleflex's stock ended a three-day winning streak.
New prostate treatment data: fewer catheters, less radiation side effects
Teleflex (NYSE: TFX) has released new clinical data at major urological congresses, highlighting the benefits of its UroLift™ System and Barrigel™ rectal spacer for prostate health. The UroLift™ System demonstrated improved early patient experience and catheter independence compared to traditional treatments for benign prostatic hyperplasia (BPH). Additionally, Barrigel™ rectal spacer showed a sustained and significant reduction in gastrointestinal toxicity for prostate cancer patients undergoing radiation therapy.
Teleflex Maintains Outlook Amid Divestiture Restructuring
Teleflex Incorporated maintained its 2026 financial outlook despite a net loss from continuing operations in the first quarter, which was attributed to restructuring efforts and planned divestitures. The company reported a significant increase in revenue due to acquisitions and reaffirmed its full-year guidance for both revenue growth and adjusted diluted earnings per share. Teleflex plans to use proceeds from divestitures to fund a $1 billion share repurchase program and reduce debt, and also announced a new CEO and additional governance measures.
Teleflex Inc. stock outperforms competitors on strong trading day
Teleflex Inc. (TFX) stock rose 1.84% to $135.18 on Wednesday, outperforming the S&P 500 Index and the Dow Jones Industrial Average on a strong trading day. This marks the third consecutive day of gains for the company's shares.
Teleflex (NYSE: TFX) director receives RSU and stock option awards
Teleflex Inc. director Candace H. Duncan was granted 1,090 shares as a Restricted Stock Unit Award and a Stock Option Award for 2,397 shares with an exercise price of $129.71. Both awards vest 100% on the one-year anniversary of the May 15, 2026 grant date, with potential for earlier vesting if she does not stand for re-election in 2027 under specific conditions. This Form 4 filing details these compensation-related equity awards and not open-market transactions.
Teleflex Inc. stock outperforms competitors on strong trading day
Teleflex Inc. (TFX) stock rose 1.79% to $132.74 on Tuesday, defying a general market downturn where the S&P 500 Index and Dow Jones Industrial Average both fell. This marks the second consecutive day of gains for Teleflex, highlighting its strong performance relative to competitors.
Teleflex stock (US8793691069): medical device specialist in focus after latest earnings
Teleflex, a medical device company specializing in single-use products for critical care and surgery, reported its latest quarterly results, showing moderate revenue growth and improved adjusted profitability. The company updated its full-year guidance, indicating continued confidence in its core product lines. Key revenue drivers include vascular access, interventional, and anesthesia products, with growth influenced by hospital procedure volumes and innovation in minimally invasive technologies.
TFX News | TELEFLEX INC (NYSE:TFX)
This article provides recent news and analysis for Teleflex Inc. (NYSE:TFX), including its current stock price and performance related to Q1 estimates, Q4 earnings, and a major divestiture plan. It also highlights the company's showcase of new clinical data for its UroLift™ System and Barrigel™ Rectal Spacer, and announces its quarterly dividend. Several entries from ChartMill also suggest TFX as a compelling value investment with strong fundamentals.
Teleflex Incorporated (TFX) Stock Analysis: Exploring a 10.76% Upside in the Healthcare Sector
Teleflex Incorporated (TFX), a medical instruments and supplies company, is poised for a potential 10.76% upside, trading at $129.71 with a $5.74 billion market cap. While it shows strong revenue growth of 32.30% and is supported by analyst recommendations, concerns exist regarding its negligible net income, low EPS, negative free cash flow, and a high dividend payout ratio. Investors should carefully assess its strategic outlook and diverse product portfolio against these financial challenges.
How Dividend, Buybacks and Reaffirmed 2026 Outlook Will Impact Teleflex (TFX) Investors
Teleflex (TFX) recently announced a cash dividend, reaffirmed its 2026 financial guidance, and outlined plans for buybacks and debt reduction. These actions emphasize capital discipline and returning cash to shareholders, even as the company reported a first-quarter net loss. Investors should consider how these strategies, along with the integration of BIOTRONIK and ongoing market pressures, might shape Teleflex's future performance and investment appeal.
T. Rowe Price (NYSE: TFX) reports 3.84M Teleflex shares, 8.7%
T. Rowe Price Investment Management filed an amended Schedule 13G/A, reporting beneficial ownership of 3,836,207 shares of Teleflex Inc. common stock, which represents 8.7% of the class. The filing specifies 3,824,270 shares with sole voting power and 3,836,207 shares with sole dispositive power. Notably, the filing explicitly denies that T. Rowe Price Investment Management is the beneficial owner of these securities.
Teleflex Announces Quarterly Dividend
Teleflex Incorporated announced that its Board of Directors has declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable on June 30, 2026, to shareholders of record as of May 25, 2026. Teleflex is a global provider of medical technologies across various therapy areas.
Teleflex declares $0.34 quarterly dividend payable June 30 By Investing.com
Teleflex Incorporated has declared a quarterly cash dividend of $0.34 per share, payable on June 30, 2026, to shareholders of record as of May 25, 2026. This medical technology company boasts a 50-year streak of consecutive dividend payments and appears undervalued according to InvestingPro's Fair Value analysis. Positive analyst outlooks from Mizuho and RBC Capital, following strong Q1 2026 results and a new CEO announcement, further underscore confidence in Teleflex's future.
Teleflex Announces Quarterly Dividend
Teleflex Incorporated has announced a quarterly cash dividend of $0.34 per share of common stock. This dividend will be payable on June 30, 2026, to shareholders who are on record as of May 25, 2026. The company, a global provider of medical technologies, stated its commitment to improving healthcare through its diverse portfolio and trusted brands.
Teleflex declares $0.34 quarterly dividend payable June 30
Teleflex Incorporated (NYSE:TFX) announced a quarterly cash dividend of $0.34 per share, payable on June 30, 2026, to shareholders of record by May 25, 2026. This dividend, reflecting a 1.04% yield, continues the medical technology company's 50-year streak of payments. The announcement follows strong Q1 2026 results and positive analyst outlooks, including raised price targets from Mizuho and RBC Capital.
Teleflex Incorporated Announces Quarterly Dividend, Payable on June 30, 2026
Teleflex Incorporated has announced a quarterly cash dividend of 34 cents ($0.34) per share of common stock. This dividend is scheduled for payment on June 30, 2026, to shareholders who are on record at the close of business on May 25, 2026.
Tejara Capital Ltd Acquires 69,700 Shares of Teleflex Incorporated $TFX
Tejara Capital Ltd significantly increased its stake in Teleflex Incorporated by 871.3% in Q4, purchasing 69,700 additional shares to hold a total of 77,700 shares valued at approximately $9.48 million. Teleflex exceeded first-quarter EPS and revenue estimates, reporting $1.39 EPS and $548.3 million in revenue, a 32.3% year-over-year increase. Despite strong financial results, market sentiment remains cautious due to concerns about margin pressure and profitability, leading analysts to maintain a consensus "Hold" rating with an average target price of $144.
Teleflex Keeps Quarterly Dividend at $0.34 a Share, Payable June 30 to Holders of Record May 25
Teleflex Incorporated announced it will maintain its quarterly dividend at $0.34 per share. The dividend is payable on June 30, 2026, to shareholders of record as of May 25, 2026. This news comes amidst other recent company updates, including an analyst upgrade and financial results for Q1 2026.
Teleflex stock (US8793691069): Q1 earnings beat with revenue up 32%
Teleflex Incorporated (NYSE: TFX) reported strong first-quarter 2026 results, with EPS of $1.39, exceeding estimates by $0.18, and revenue up 32.3% year-over-year. Despite the revenue growth, the stock saw a post-earnings dip due to margin pressures, with operating profit down 52.1%. Teleflex, a medical technology company specializing in critical care and surgical products, remains a key player in the medtech industry, benefiting from an aging population and increasing procedural demand.
Teleflex Incorporated $TFX Shares Acquired by Baader Bank Aktiengesellschaft
Baader Bank Aktiengesellschaft significantly increased its stake in Teleflex Incorporated during the fourth quarter, reflecting a broader interest from institutional investors who now own over 95% of the company. Teleflex also reported better-than-expected Q1 earnings and revenue, leading to raised FY2026 EPS guidance. Despite mixed analyst sentiment and concerns over margin compression, the company announced a quarterly dividend.
TFX Stock Down Post Q1 Earnings & Revenue Beat, Margins Crash
Teleflex Inc. (TFX) reported mixed results for Q1 2026, with adjusted EPS and revenues beating Zacks Consensus Estimates, but GAAP loss per share and margins significantly contracting. The company's stock fell 2% post-announcement, driven by a substantial decline in gross and operating margins despite growth in key segments like Vascular and Surgical. Teleflex maintained its full-year 2026 revenue and adjusted EPS guidance, indicating anticipation of future improvements.
First Eagle Investment Management LLC Buys 52,300 Shares of Teleflex Incorporated $TFX
First Eagle Investment Management LLC significantly increased its stake in Teleflex Incorporated (NYSE:TFX) by 163.4% in the fourth quarter, adding 52,300 shares to reach a total of 84,300 shares valued at approximately $10.3 million. This comes after Teleflex reported better-than-expected quarterly earnings and revenue, and reaffirmed its FY2026 EPS guidance. While Wall Street sentiment is mixed with a "Hold" consensus rating, some analysts like Truist and Needham have raised their price targets for the medical technology company.
Teleflex (NYSE: TFX) interim CEO uses 289 shares for tax withholding
Teleflex interim President and CEO Stuart A. Randle reported a routine tax-related share disposition where 289 shares of Common Stock were withheld at $133.06 per share to cover tax liabilities upon the vesting of a restricted stock unit award. After this transaction, Randle directly holds 19,583 shares. This event is a common procedure for equity compensation and does not signify a market sale but rather a statutory tax obligation.
Teleflex Names Medtronic Executive CEO After Restructuring
Teleflex Incorporated has appointed Jason Weidman, a former Medtronic executive, as its new CEO, succeeding Stuart Randle. This leadership change comes as Teleflex undergoes a restructuring focused on higher-growth hospital and interventional care markets following recent divestitures. The company plans to deploy capital towards debt reduction and shareholder returns, with approximately $1 billion in share repurchases and $800 million in debt reduction expected.
Research Analysts Issue Forecasts for Teleflex Q1 Earnings
Research analysts have issued their Q1 earnings forecasts for Teleflex (NYSE:TFX). Needham & Company LLC projects Q1 2028 EPS of $2.90 and FY2028 EPS of $12.18, maintaining a "Buy" rating and a $147 price target. Despite mixed analyst sentiment, Teleflex's last quarterly report beat expectations, with $1.39 EPS and $548.3 million in revenue, leading to a reaffirmed FY 2026 guidance.
Teleflex Inc. stock underperforms Monday when compared to competitors
Teleflex Inc. (TFX) shares fell by 2.51% on Monday, closing at $129.72, despite an overall positive trading session for the broader market. This drop ended a four-day winning streak for Teleflex stock. The S&P 500 Index and the Dow Jones Industrial Average both saw gains on the same day.
Truist Financial Reiterates "Hold" Rating for Teleflex (NYSE:TFX)
Truist Financial has reiterated a "Hold" rating for Teleflex (NYSE: TFX) and increased its price target to $143, indicating a potential 9.9% upside. This comes after Teleflex recently surpassed quarterly earnings and revenue estimates. Other analyst opinions are mixed but generally constructive, with a consensus "Hold" rating and an average price target of $144.
Teleflex stock (US8793691069): Q1 beat and buyback announcement
Teleflex Inc. reported better-than-expected Q1 2026 earnings, with adjusted EPS of $1.39 and revenue of $548.3 million, topping analyst estimates. The company also announced a stock buyback program, although its full-year EPS guidance of $6.25 to $6.55 fell short of the $6.73 consensus. Teleflex, a medical device maker, maintained its full-year outlook despite the tempered guidance, reflecting strong performance in its core business segments.
Teleflex (TFX) Is Up 6.3% After Q1 Beat, CEO Change And Reaffirmed 2026 Guidance - What's Changed
Teleflex (TFX) reported stronger-than-expected Q1 2026 results, with sales of US$548.26 million, though it swung to a net loss of US$8.15 million. The company reaffirmed its 2026 GAAP revenue and EPS guidance and appointed Jason Weidman as the new CEO, signaling a continued focus on higher-acuity hospital markets and cost savings. Despite the positive Q1 performance, the article highlights ongoing risks related to margin pressure from restructuring and integration costs.
UBS Group AG Trims Stock Position in Teleflex Incorporated $TFX
UBS Group AG reduced its stake in Teleflex Incorporated by 43.6% in the fourth quarter of 2025, selling over 173,000 shares. Despite this, Teleflex reported strong Q1 results, exceeding analyst expectations for EPS and revenue, though its full-year 2026 EPS guidance fell short of market expectations. The company also announced a share buyback plan and received several analyst price target increases.
Teleflex (TFX) Is Up 6.3% After Q1 Beat, CEO Change And Reaffirmed 2026 Guidance - What's Changed
Teleflex (TFX) reported stronger-than-expected first-quarter 2026 results, with sales increasing significantly but swinging to a net loss. The company reaffirmed its 2026 GAAP revenue and EPS guidance, announced portfolio reshaping plans, and appointed Jason Weidman as the new CEO. This signals a continued focus on higher-acuity hospital markets, cost savings, and capital returns, supporting the investment thesis despite ongoing margin and execution risks.
Teleflex (NYSE:TFX) Issues Earnings Results, Beats Estimates By $0.18 EPS
Teleflex (NYSE:TFX) reported strong earnings, with adjusted EPS of $1.39 and revenue of $548.3 million, surpassing analyst estimates. The company's revenue increased by 32.3% year-over-year, and it updated its FY2026 EPS guidance to $6.25–$6.55. Teleflex also announced plans to use approximately $1.8 billion from strategic divestitures for a share repurchase program and debt repayment, while navigating near-term margin pressures and supplier recalls.
Teleflex Incorporated (NYSE:TFX) Receives Average Rating of "Hold" from Brokerages
Teleflex Incorporated (NYSE:TFX) has received a consensus "Hold" rating from nine brokerages, with an average 1-year price target of approximately $142.86. Despite beating Q1 earnings and revenue estimates, the company's FY2026 EPS guidance fell below market expectations, contributing to a cautious outlook from analysts. Teleflex also pays a quarterly dividend of $0.34, yielding 1.0% annually, and institutional investors hold 95.62% of its stock.
TFX SEC Filings - Teleflex Inc 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Teleflex Inc.'s (TFX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, and 8-K material event forms. It details how these filings offer information on financial performance, strategic transactions like asset sales, leadership changes, and use of non-GAAP measures. The article also highlights Stock Titan's AI-powered tools that summarize disclosures and analyze sentiment for investors.
Teleflex Inc. stock outperforms competitors on strong trading day
Teleflex Inc. (TFX) shares rose 1.05% to $133.06 on Friday, marking its fourth consecutive day of gains. This performance outpaced the broader market, with the S&P 500 Index and Dow Jones Industrial Average also seeing increases. The article highlights Teleflex's strong trading day relative to its competitors.
Teleflex Posts Q1 Results, Maintains 2026 Outlook, Plans Buyback
Teleflex reported strong first-quarter 2026 results with significant revenue growth from continuing operations, despite a diluted EPS loss. The company reaffirmed its 2026 guidance, highlighting growth in its Interventional and Surgical segments, and announced plans for a $1 billion share repurchase, debt reduction, and a leadership transition. Analysts currently rate TFX stock as a Hold, acknowledging recent financial challenges but noting positive future plans.
RBC Upgrades Teleflex to Outperform From Sector Perform, Raises Price Target to $155 From $135
RBC Capital Markets has upgraded its rating for Teleflex Inc. (TFX) from "Sector Perform" to "Outperform," simultaneously increasing the price target to $155 from the previous $135. This revised outlook comes shortly after Teleflex reported its first-quarter earnings for 2026, where adjusted earnings per share declined while revenue increased, leading the company to reiterate its fiscal 2026 guidance. The upgrade suggests a positive reassessment of the medical technology company's future performance by RBC.
Teleflex beats Street in Q1, maintains guidance
Teleflex reported first-quarter results that surpassed Wall Street expectations, despite a net loss attributable to discontinued operations. The medical device company saw robust sales growth across its continuing businesses, particularly in Interventional revenues, and maintained its full-year 2026 guidance. Teleflex is also proceeding with the planned sale of certain businesses and intends to use the proceeds for share repurchases and debt reduction.
Teleflex Inc. stock outperforms competitors on strong trading day
Teleflex Inc. (TFX) saw its stock price rally by 6.86% to $131.68 on Thursday, despite a generally poor trading session for the broader market. This performance marked the stock's third consecutive day of gains, as the S&P 500 Index and Dow Jones Industrial Average both declined.
Teleflex Incorporated 2026 Q1 - Results - Earnings Call Presentation (NYSE:TFX) 2026-05-07
Teleflex Incorporated has published its Q1 2026 earnings call presentation. The article, written by SA Transcripts, highlights the company's financial results for the quarter. This publication provides investors with insights into Teleflex's performance.
Earnings call transcript: Teleflex Q1 2026 beats earnings expectations, stock rises
Teleflex reported strong Q1 2026 results, exceeding earnings and revenue expectations with an adjusted EPS of $1.39 and revenue of $548.3 million. Despite facing margin pressures from tariffs and logistics costs, the company's strategic transformation, including planned divestitures and a share repurchase program, remains on track. Teleflex is also investing heavily in R&D, particularly for its Freesolve drug-eluting scaffold technology, with optimistic future guidance for 2027 and beyond.
Teleflex: Q1 Earnings Snapshot
Teleflex Inc. (TFX) reported a first-quarter loss of $8.2 million, or 18 cents per share, which was better than Wall Street's expectations. The company's adjusted earnings per share were $1.39, surpassing the average analyst estimate of $1.21. Teleflex also exceeded revenue forecasts, posting $548.3 million for the period and projecting full-year revenue between $2.28 billion and $2.3 billion.
Teleflex (NYSE: TFX) Q1 2026 revenue jumps 32% as EPS turns negative
Teleflex reported Q1 2026 revenue of $548.3 million, a 32.3% year-over-year increase, with GAAP diluted EPS turning negative at $(0.11) while adjusted diluted EPS was $1.39. The company maintained its full-year 2026 financial outlook, including revenue growth and adjusted EPS guidance, and expects its Strategic Divestitures to close in the second half of 2026, with proceeds earmarked for share repurchases and debt reduction. Jason Weidman has been appointed President and CEO, effective June 8, 2026.
Teleflex Reports First Quarter Financial Results and Full Year 2026 Outlook
Teleflex Incorporated announced its financial results for the first quarter ended March 31, 2026, reporting revenue from continuing operations of $548.3 million, a 32.3% increase compared to the prior year. The company maintained its full-year 2026 guidance, expecting GAAP revenue growth of 14.40% to 15.40% and adjusted diluted EPS from continuing operations of $6.25 to $6.55. Teleflex also highlighted its strategic divestitures set to close in the second half of 2026, aiming to return capital to shareholders and reduce debt.
Teleflex Inc. stock outperforms competitors on strong trading day
Teleflex Inc. (TFX) shares rose 2.10% to $123.23 on Wednesday, marking its second consecutive day of gains. The stock's performance outpaced the broader market, which also experienced a favorable trading session with the S&P 500 Index and Dow Jones Industrial Average both seeing increases.
Strs Ohio Acquires 11,002 Shares of Teleflex Incorporated $TFX
Strs Ohio increased its holdings in Teleflex Incorporated by 47.7% in the fourth quarter, acquiring an additional 11,002 shares and bringing its total ownership to 34,058 shares valued at $4.16 million. Other institutional investors like AQR Capital Management LLC and Dimensional Fund Advisors LP also significantly adjusted their stakes in the medical technology company. Teleflex's stock has seen a 0.7% increase, trading at $120.70, with a market capitalization of $5.34 billion, and the company recently announced a quarterly dividend of $0.34 per share.
Teleflex Incorporated $TFX Shares Sold by Vanguard Group Inc.
Vanguard Group Inc. reduced its stake in Teleflex Incorporated by 0.8% in the fourth quarter, selling 37,795 shares but still holding 4,759,015 shares valued at approximately $580.8 million. The medical technology company recently missed quarterly earnings and revenue estimates significantly but provided FY2026 EPS guidance of $6.25–$6.55. Analyst ratings are mixed, with a consensus "Hold" rating and an average price target of $133.57.
